8th Annual Dana-Farber/Harvard Cancer Center Lung Cancer Program Symposium
Friday, May 10, 8:30 a.m. to 4:00 p.m.
JB Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston
The symposium is designed to bring together investigators from the different scientific disciplines from the Harvard Medical School affiliated institutions and leading cancer centers to share the latest advances in lung cancer.
- Characterization of gastrointestinal carcinoid tumors and the application of targeted therapy. Matthew Kulke, MD, Director, Program in Neuroendocrine and Carcinoid Tumors, DFCI, Associate Professor of Medicine, HMS
- Use of whole genome outlier analysis to identify novel biomarkers of drug sensitivity. David B. Solit, MD , Associate Member, Human Oncology and Pathogenesis Program, Associate Attending Physician, Genitourinary Oncology Service, Associate Professor of Medicine, Weill Cornell Medical College, Associate Professor of Cell and Developmental Biology, Weill Cornell Graduate School of Medical Sciences at Cornell University
- Therapeutic implications of targeting PD1 and PDL1 in lung cancer. Gordon J. Freeman, PhD, Associate Professor, Department of Medicine, HMS
- Mechanisms of Protective Tumor Immunity. Glenn Dranoff, MD, Professor, Department of Medicine, HMS; Director, Human Gene Transfer Laboratory Core, DFCI, Co-Leader, Cancer Vaccine Center, Medical Oncology, DFCI
- Award winning abstract speakers (5 TBA) in 4 categories: 1) Risk, prevention and disparities; 2) Cell biology and signaling; 3) Clinical/translational studies; 4) Genetics and genomics
The symposium is offered without charge to all DFHCC lung cancer researchers. Advance registration is required and includes the program, continental breakfast and lunch. Seating is limited, first come, first served, and RSVPs are required by Friday, April 26. If you wish to submit an abstract or attend, please contact Joy McGugan for details and/or a registration form at email@example.com.